Elicit vs EviSynth

Elicit is an AI research assistant for researchers gathering and assessing evidence. Its Research Agent draws on scientific databases, academic journals, public data sources, uploaded documents, a corpus of 138 million academic papers, and the wider web. A session can use up to 20 uploaded resources, including PDF, DOCX, XLSX, PPTX, and JPG files. Elicit offers Research Agent sessions, Research Reports, and Systematic Reviews, and supports AI-generated claims with sentence-level citations to underlying sources. It can find up to 1,000 relevant papers and analyze up to 20,000 data points at once. Research Reports export as PDF or Word, tables as CSV or Excel, and references as RIS or BIB. Elicit runs on the web and provides an API, but API access requires Pro or above. Its MCP server connects to Claude Desktop, Claude Code, and other compatible clients using OAuth 2.0. Basic is free with limited usage for Research Agent and Research Reports; Plus costs $11 a month. Pro is $39 a month and Scale is $89 a month. Elicit states that it has achieved SOC 2 Type II compliance.

EviSynth is a platform for evidence syntheses and systematic reviews, available on Android, iOS, and the web. Its screening workflow uses a language model to assess abstracts against PICO criteria and suggest inclusion or exclusion. Built-in risk-of-bias tools support RoB 2, ROBINS-I, and custom checklists. Teams can invite collaborators, resolve conflicts, and track who screened each item and when. The AI Insights tab provides summaries, keyword extraction, and bias hints. References can be imported as EndNote XML or PubMed NBIB files, and the screening interface is designed for touch-screen use on mobile devices. The maker describes access as free for academic use, with no trials or subscriptions, and says no credit card is required to start. The platform is open source and presented for researchers, including students and faculty conducting rapid or full systematic reviews. The listed academic plan includes unlimited collaborators. The homepage credits Milad Mirmoghtadaei, M.D. as developer.